Head of Investor Relations
Boston Scientific Corp (BSX)Equibles does not estimate personal net worth.
Get an email with a short summary when Boston Scientific Corp publishes a filing, an earnings call transcript or a press release.
Get BSX alertsJonathan Monson is recorded as CFO at Boston Scientific Corp (BSX) since June 30, 2025 and Head of Investor Relations at Boston Scientific Corp (BSX). Boston Scientific Corp reported in an 8-K filed April 23, 2025 that Jonathan Monson was appointed Executive Vice President and Chief Financial Officer, effective June 30, 2025. Boston Scientific Corp reported in an 8-K filed January 31, 2024 that Jonathan Monson was appointed Senior Vice President, Investor Relations, effective March 1, 2024. The proxy statement of Boston Scientific Corp reports total compensation of $6,083,679 for Jonathan Monson in fiscal 2025, including a base salary of $591,848. Jonathan Monson has spoken on 4 earnings calls across 1 company, most recently for Boston Scientific Corp on October 22, 2025. Boston Scientific Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Boston Scientific Corp includes Michael Mahoney (CEO), Joe Fitzgerald (COO), Jodi Euerle Eddy (CIO) and 7 others.
“On April 23, 2025, Boston Scientific Corporation (the "Company") announced that Daniel J. Brennan has decided to retire from his role as Executive Vice President and Chief Financial Officer of the Company effective as of June 29, 2025, and that Jonathan Monson, who currently serves as Senior Vice President, Investor Relations, has been promoted to Executive Vice President and Chief Financial Officer of the Company effective as of June 30, 2025.”
“the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) appointed Jonathan Monson as Senior Vice President, Investor Relations, effective March 1, 2024.”
“Third quarter consolidated revenue of $5.065 billion represents 20.3% reported growth versus the third quarter of 2024 and includes a 90 basis point tailwind from foreign exchange, which was favorable versus our expectations.”
“With me today are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and Dan will be joined by our Chief Medical Officer, Dr. Ken Stein.”
“We expect full-year 2025 adjusted below-the-line expense to be approximately $425 million. Under current legislation, including enacted laws and issued guidance, we forecast a full-year 2025 operational tax rate of approximately 13.5%, and an adjusted tax rate of approximately 12.5%.”
“With me today are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and Dan will be joined by our Chief Medical Officer, Dr. Ken Stein, and Art Butcher, President of our MedSurg and Asia Pacific businesses.”
2025-06-30–present
SEC 8-K
2024-03-01–present
Medical Devices · Healthcare
Head of Investor Relations, CFO
2024-03-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Boston Scientific Corp (BSX) | Executive Vice President and Chief Financial Officer | $591,848 | $6,083,679 |
